Navigation Links
Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer

Nearly 50,000 Americans are diagnosed each year with stage III or locally advanced NSCLC, for which surgery is usually not a viable treatment option. Optimizing nonsurgical treatment strategies for these patients is an ongoing research endeavor. In an article published online September 8, 2011 in the Journal of the National Cancer Institute, RTOG researchers report that treating patients with concurrent chemotherapy and radiation therapy significantly increased five‑year survival rates compared with treating patients with radiation therapy upon completion of chemotherapy treatment.

"The significant increase in five-year survival for patients receiving concurrent versus sequential treatment establishes a new treatment standard for this large population of lung cancer patients," says Walter J. Curran, Jr., M.D., RTOG Group Chair, the trial's principal investigator and Executive Director of the Winship Cancer Institute of Emory University in Atlanta. "It is likely the chemotherapy makes the tumor cells more sensitive to radiation therapy, which contributed to the improved long-term patient benefit seen with concurrent therapy," adds Curran.

A total of 610 study participants at 153 institutions across North America were enrolled into the phase III trial and were randomized to receive cisplatin-based chemotherapy in addition to radiation therapy administered sequentially (arm 1), once daily concurrently (arm 2) or twice daily concurrently (arm 3). The percentages of study participants confirmed still living at five years post-treatment in study arms 1, 2 and 3 were 10 percent, 16 percent and 13 percent, respectively. "The significant survival benefit of concurrent treatment confirms the promising results observed in a similar RTOG phase II trial and corroborates the results of a 314-patient Japanese trial and several smaller European trials," says Jeffrey D. Bradley, M.D., Director of the S. Lee Kling Center for Proton Therapy at the Siteman Cancer Center, Washington University School of Medicine in St Louis and RTOG Lung Cancer Committee Chair. "The survival gain related to concurrent treatment was most prominent in arm 2 for which the only difference in treatment compared with arm 1 was the timing of the radiation therapy delivery."

The authors also report that study participants experienced significantly worse side effects with concurrent therapy versus sequential therapy, particularly, severe esophagitis (inflammation of the esophagus lining). However, data collected from study participants, who were followed for a median of 11 years after treatment show that late side effects occurring months or years after treatment were minimal and similar across the three study arms.

Medical oncologist Corey J. Langer, M.D, Director of Thoracic Oncology at the Abramson Cancer Center, University of Pennsylvania in Philadelphia and research co-author states, "Many patients initially diagnosed with inoperable stage III disease are too ill to tolerate the more aggressive concurrent therapy administered in this trial. We are encouraged, however, that new radiation therapy techniques and chemotherapy drugs developed since the trial's conductsome currently under investigationhave the potential to increase the benefit of concurrent therapy. It is critical for RTOG and other groups to continue their investigation of new treatments to improve cancer survival and minimize treatment side effects."


Contact: Heather Curry
American College of Radiology

Related medicine news :

1. New study introduces the prospect for concurrent antiangiogenic/antitumorigenic therapy
2. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
3. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
4. Scientists identify microRNA as possible cause of chemotherapy resistance
5. Study evaluates costs and benefits of new chemotherapy drugs
6. Older Colon Cancer Patients Less Likely to Get Chemo
7. Are New Chemo Treatments Cost-Effective?
8. BioSphere Medical's HepaSphere Microspheres Safely Deliver Doxorubicin in Liver Cancer Chemoembolization Therapy -- Study Presented at SIR
9. Researchers find new chemotherapy combination shows promise in endometrial cancer
10. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
11. Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS
Post Your Comments:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... 2016 Revolutionary technology includes multi-speaker ... , industry leaders in advanced audiology and hearing aid ... Opn ™, the world,s first internet connected hearing aid ... devices.      (Photo: ) ... of ,world firsts,: , TwinLink™ - the ...
Breaking Medicine Technology: